Lantern Pharma Inc. 8-K

What Happened
Lantern Pharma Inc. (LTRN) filed a Form 8-K on March 30, 2026 to announce that it will issue a press release reporting its financial results for the fiscal year and fourth quarter ended December 31, 2025. The company also disclosed it will use a prepared presentation during a conference call and live webinar on March 30, 2026 to discuss those financial and operating results. The press release and presentation are furnished as exhibits to the 8-K.

Key Details

• Filing date: March 30, 2026; reporting period: fiscal year and Q4 ended December 31, 2025.
• Item 2.02: Results of Operations and Financial Condition — press release furnished as Exhibit 99.1.
• Item 7.01: Regulation FD Disclosure — presentation for the conference call/webinar furnished as Exhibit 99.2.
• Item 9.01: Exhibits include Exhibit 99.1 (press release), Exhibit 99.2 (presentation) and Exhibit 104 (Inline XBRL cover page).

Why It Matters
This 8-K signals that Lantern will publicly disclose its full FY and Q4 2025 financial results and host management commentary, which can affect investor decisions. Retail investors should review the furnished press release and presentation (Exhibits 99.1 and 99.2) or listen to the call/webinar to see revenue, earnings, cash position, guidance (if provided), and management’s discussion of operations. The Form 8-K itself notifies investors of the release and provides links to the exhibits where the detailed financial information will appear.